Abstract:

Objective To explore the plasma levels of D-dimer in non-small cell lung cancer（NSCLC） patients and its clinical significance. MethodsPlasma D-dimer levels in 215 NSCLC patients，90 patients with benign lung disease and 60 healthy people were measured by enzyme linked immunosorbent assay（ELISA）.The patients were followedup for one year. The rates of relapse and metastasis in operative patients was recorded, and median survival of patients received chemotherapy was measured. Results The plasma D-dimer levels of NSCLC group，benign lung disease group and normal control group were（1.73±0.26）mg／L，（0.26±0.03）mg／L and（0.23±0.01）mg／L，respectively. The levels of NSCLC group were significantly higher than those of benign lung disease group and control group（P＜0.05）.The plasma D-dimer levels of Ⅲ-Ⅳstage NSCLC patients was（2.31±0.34）mg／L, which was higher than （0.87±0.38）mg/L in theⅠ-Ⅱstage patients（P＜0.05）. The positive rates of D-dimer after operation in 105 NSCLC patients was 28.6%（30／105），which was significantly lower than that of preoperative patients（49.5%）. But there was no significant change of D-dimer after chemotherapy. The rates of relapse and metastasis in patients with a positive D-dimer preoperatively（28.8％） was higher than those with a negative D-dimer（5.7％）, the difference was statistically significant（P＜0.05）. The median survival for patients with a positive D-dimer before chemotherapy was 8.7 months, which was shorter than those with a negative D-dimer（12.8 months）, the difference was statistically significant（P＜0.05）. Conclusion The plasma levels of D-dimer is closely related to tumor staging and can also be used to determine effects of surgery and evaluation of prognosis.